Gallipoli Medical Research Revenue and Competitors
Employee Data
- Gallipoli Medical Research has 68 Employees.
- Gallipoli Medical Research grew their employee count by 31% last year.
Gallipoli Medical Research's People
Name | Title | Email/Phone |
---|
Gallipoli Medical Research Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | N/A | 82 | 19% | N/A | N/A |
#2 | N/A | 212 | 5% | N/A | N/A |
#3 | N/A | 68 | 31% | N/A | N/A |
#4 | N/A | 72 | 20% | N/A | N/A |
#5 | N/A | 4 | 0% | N/A | N/A |
#6 | N/A | 858 | 4% | N/A | N/A |
#7 | N/A | 61 | 20% | N/A | N/A |
#8 | N/A | 52 | 49% | N/A | N/A |
#9 | N/A | 63 | 24% | N/A | N/A |
#10 | N/A | 90 | 27% | N/A | N/A |
What Is Gallipoli Medical Research?
Gallipoli Medical Research works to lessen the impact of disease today while also searching for the cures of tomorrow by:\n\nWorking to alleviate the burden of disease impacting our Veteran community\n\nProviding the infrastructure, governance and resources to support approved research endeavours\n\nConducting and funding translational laboratory research; research that can have the quickest movement from ‘bench to bedside’\n\nFacilitating and supporting a culture of medical research within Greenslopes Private Hospital and other related partners through competitive scholarships and grants\n\nDelivering high quality clinical trials of emerging new therapies for the benefit of our patients and the wider community\n\nSharing our results for the greatest benefit of all, thereby increasing community and corporate support for the Foundation and its research\n\n \n\n \n \n Show more\n \n\n \n\n\n \n \n Show less
keywords:N/AN/A
Total Funding
68
Number of Employees
N/A
Revenue (est)
31%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | N/A | 68 | 62% | N/A |
#2 | $19.9M | 68 | -11% | N/A |
#3 | $15.5M | 68 | 10% | N/A |
#4 | N/A | 68 | 58% | N/A |
#5 | $15M | 68 | 6% | N/A |